https://allianceequityresearch.com/insights/5e-bought-a-147-million-revenue-boron-business-for-roughly-36-million-but-the-discount-comes-with-real-riskAlliance Equity Researchen2026-10-035E Bought a $147 Million Revenue Boron Business for Roughly $36 Million, but the Discount Comes With Real Risk https://allianceequityresearch.com/insights/surrozens-fda-clearance-unlocks-95-million-and-a-clinical-testAlliance Equity Researchen2026-10-03Surrozen’s FDA Clearance Unlocks $95 Million and a Clinical Test https://allianceequityresearch.com/insights/foghorn-lost-its-lilly-partnership-but-the-40-workforce-cut-changes-the-valuation-mathAlliance Equity Researchen2026-10-02Foghorn Lost Its Lilly Partnership, but the 40% Workforce Cut Changes the Valuation Math https://allianceequityresearch.com/insights/onsemi-cut-1-3-billion-from-its-synaptics-deal-and-made-both-stocks-more-valuableAlliance Equity Researchen2026-10-02Onsemi Cut $1.3 Billion From Its Synaptics Deal and Made Both Stocks More Valuable